

CORPORATE OVERVIEW

Kashiv BioSciences, founded in 2011, has evolved into a premier, fully-integrated biopharmaceutical company offering next generation drug delivery technologies, specialty pharmaceutical products, complex generics, and affordable biosimilars. It operates from four different R&D locations that provide formulation development, analytical testing, biosimilar characterization, and manufacturing of small and large molecules. We plan to commercialize our products via strategic partnerships and profit sharing arrangements.

Kashiv Specialty Pharmaceuticals (KSP) is a wholly-owned subsidiary of Kashiv BioSciences, formed to develop complex generics, innovative drug delivery platforms, and novel 505(b)(2) drugs. KSP targets clinical unmet needs of patients suffering from orphan, chronic, and debilitating diseases to improve efficacy, safety, affordability, and overall quality of life.

LEADERSHIP

The company's scientific and business executives have extensive industry experience in developing advanced drug delivery technologies, making novel products, and creating high-value enterprises. Kashiv was founded by Dr. Navnit Shah, a world-renowned pharmaceutical scientist and former Head of R&D at Roche. Kashiv's leadership team has prior senior management experience at major and specialty pharmaceutical companies e.g. Roche, Pfizer, Amneal, Enzon, Noven and Antares.

BUSINESS UNITS

Kashiv BioScience develops advanced drug delivery technologies; a clinical-stage pipeline of differentiated 505(b)(2) NDA products; two advanced & several early-stage biosimilar products and manufacturing; and early-stage prodrugs that significantly improve the performance of known molecules.

KSP DRUG DELIVERY

Next generation technologies for improved oral drug delivery

- GRANDE™ – gastric retention systems
- KRONOTEC™ – timed release technology
- R&D Center in Bridgewater, NJ

BIOSIMILARS

Fully Integrated Development Infrastructure

- Products in late-stage development
- Mammalian and Microbial Platforms
- R&D and Manufacturing Facilities in Chicago, IL, Piscataway, NJ & Gujarat, India

KSP 505(b)(2) PRODUCTS

Portfolio of Differentiated Products in Clinical Development

- Orals
- Injectable
- Development and cGMP Manufacturing in Bridgewater, NJ

PRODRUGS

- Initial targets are known drugs requiring improved safety and efficacy
- Lead candidates in preclinical development
- New state-of-the-art R&D center in Gujarat, India

KSP, BRIDGEWATER
995 US HWY 202/206
BRIDGEWATER, NJ 08807
908.895.1520

PISCATAWAY
20 NEW ENGLAND AVENUE
PISCATAWAY, NJ 08854
732.475.0500

CHICAGO
3440 S. DEARBORN ST.
CHICAGO, IL 60616
312.620.1500

INDIA
FP 27/2, 43, TP-85, BLOCK-B,
OPP. APPLEWOODS TOWNSHIP
S P RING ROAD, AHMEDABAD
382210, GUJARAT, INDIA